PPARG and urinary bladder carcinoma: Similarly as for rosiglitazone, PPARγ-independent anticancer action of other synthetic PPARγ ligands such as troglitazone or ciglitazone has been reported in colon, prostate or bladder cancer cells [38–40], but the underlying mechanisms and the general frequency of these effects remain to be elucidated.